Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Equity Development
|
$100.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Hikma Pharmaceuticals Plc Completes Acquisition of Baxter Healthcare Corporation's Multi-Source Injectables Business
Hikma Pharmaceuticals Plc announced that it has completed its $112 million acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI). As required by the United States Federal Trade Commission, Hikma will divest two West-Ward products, Phenytoin and Promethazine. This will not have a material impact on Hikma's Injectables revenues and will not affect the expected contribution from Baxter's Multi-Source Injectables business.
Latest Developments for Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals Plc Reiterates FY 2012 Revenue Guidance-Conference Call
- Hikma Pharmaceuticals Plc Completes Mandatory Tender Offer, Raising Its Stake In Promopharm To 94.1%
- Hikma Pharmaceuticals Plc Launches Mandatory Tender Offer For Remaining Shares Of Société de Promotion Pharmaceutique du Maghreb S.A.
- Hikma Pharmaceuticals Plc Reiterates FY 2011 Guidance
Latest Key Developments in Pharmaceuticals
- Share this
- Link this
- Digg this
Follow Reuters